Quinnova launches Salvax in USA

The USA's Quinnova Pharmaceuticals has launched Salvax (hydrating topical foam) Rx for the treatment of hyperkeratotic conditions such as  psoriasis, keratosis pilaris and xerosis.

Salvax contains 6% salicylic acid, a potent keratolytic agent,  formulated in a water-lipid based foam. The product utilizes Quinnova's  patented Proderm Technology, containing a unique combination of  physiological lipids, dimethicone and glycerin which together help to  restore the skin barrier, hydrate and protect the skin, in addition to  having anti-inflammatory properties.

The water-lipid nature of the foam allows the ingredients to be rapidly  absorbed and incorporated into the outer layers of the skin.  Furthermore, the foam provides a cosmetically-elegant feel in addition  to ease of application because it is non-greasy and spreads easily,  especially on hairy regions of the body where the foam does not tangle  hair. Unlike some topical foam preparations, Proderm Technology does not  use either alcohol or other organic solvents, therefore it is well  tolerated by patients, Quinnova noted.